Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma.
about
Combined locoregional treatment of patients with hepatocellular carcinoma: State of the artEfficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis.Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma.Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinomaTransarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.Postoperative adjuvant TACE for patients of hepatocellular carcinoma in AJCC stage I: friend or foe? a propensity score analysis.Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria.BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A.Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study.Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma.Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma.
P2860
Q26766127-1A0984B5-464B-44F1-9C01-45E8548F558EQ35743221-6623CBBF-6C27-49CF-8BD4-EB960A59C635Q36121249-476BFDD2-3548-4352-9D42-09E25A74E1D1Q37709406-A62787D9-36E4-42A4-9380-584D9443ED13Q38691791-37EA5FB4-5844-4580-A472-DBFA55FB97E5Q38810775-969CA46F-64D2-4D01-BC43-16116B0DBC36Q40968769-557EF869-91DB-4BFF-AF01-A0D0EE429D5FQ41430971-72890156-6463-40B6-9A73-EA1D5116B9EFQ47104262-0A8F9715-0518-4AEE-9740-EB687053AB6FQ51822756-307A2725-C8A5-45B0-9C8A-7A25AA022583Q55003707-BA2FC3CA-251C-4926-AEDC-5B915DD8A19EQ55689590-8A464D4E-A338-4828-9ABF-1163E445B521
P2860
Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@ast
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@en
Transcatheter arterial chemoem ...... in patients with intermediate
@nl
type
label
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@ast
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@en
Transcatheter arterial chemoem ...... in patients with intermediate
@nl
prefLabel
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@ast
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@en
Transcatheter arterial chemoem ...... in patients with intermediate
@nl
P2093
P2860
P356
P1433
P1476
Transcatheter arterial chemoem ...... C B) hepatocellular carcinoma.
@en
P2093
Bo-Heng Zhang
Ning-Lin Ge
Yan-Hong Wang
Yu-Hong Gan
Zheng-Gang Ren
P2860
P2888
P356
10.1186/1471-2407-14-849
P407
P577
2014-11-19T00:00:00Z
P5875
P6179
1019365462